J Clin Immunol. 2026 Apr 22. doi: 10.1007/s10875-026-02023-z. Online ahead of print. NO ABSTRACT PMID:42018084 | DOI:10.1007/s10875-026-02023-z
J Clin Immunol. 2026 Apr 21. doi: 10.1007/s10875-026-02009-x. Online ahead of print. NO ABSTRACT PMID:42012700 | DOI:10.1007/s10875-026-02009-x
J Clin Immunol. 2026 Apr 21. doi: 10.1007/s10875-026-02024-y. Online ahead of print. NO ABSTRACT PMID:42012563 | DOI:10.1007/s10875-026-02024-y
J Clin Immunol. 2026 Apr 21. doi: 10.1007/s10875-026-02025-x. Online ahead of print. ABSTRACT Kawasaki disease (KD) remains the leading cause of acquired heart disease in children. While intravenous immunoglobulin (IVIG) represents standard therapy, approximately 10-20% of patients exhibit treatment refractoriness associated with significantly elevated coronary artery lesion risk. Current risk stratification relies on clinical parameters-fever … Read more
J Clin Immunol. 2026 Apr 21. doi: 10.1007/s10875-026-02019-9. Online ahead of print. NO ABSTRACT PMID:42009946 | DOI:10.1007/s10875-026-02019-9
J Clin Immunol. 2026 Apr 17. doi: 10.1007/s10875-026-02016-y. Online ahead of print. NO ABSTRACT PMID:41991796 | DOI:10.1007/s10875-026-02016-y
J Clin Immunol. 2026 Apr 16. doi: 10.1007/s10875-026-02018-w. Online ahead of print. NO ABSTRACT PMID:41986803 | DOI:10.1007/s10875-026-02018-w
J Clin Immunol. 2026 Apr 14. doi: 10.1007/s10875-026-02017-x. Online ahead of print. NO ABSTRACT PMID:41979700 | DOI:10.1007/s10875-026-02017-x
J Clin Immunol. 2026 Apr 9. doi: 10.1007/s10875-026-01997-0. Online ahead of print. NO ABSTRACT PMID:41954665 | DOI:10.1007/s10875-026-01997-0
J Clin Immunol. 2026 Apr 10. doi: 10.1007/s10875-026-01991-6. Online ahead of print. NO ABSTRACT PMID:41957131 | DOI:10.1007/s10875-026-01991-6
